A Regulatory Approval Drove Heron (HRTX) Stock Higher

Heron Therapeutics, Inc. (NASDAQ: HRTX) witnessed a notable surge in its stock during the preceding trading session, marking an 18.86% increase to settle at $2.6150. An important regulatory clearance caused this increase in Heron’s stock price. An important regulatory clearance caused this increase in Heron’s stock price.

Heron (HRTX) has officially declared that the U.S. Food and Drug Administration (FDA) has given the green light to its additional New Drug Application (NDA). The approved NDA for ZYNRELEF extended-release solution aims to broaden the product’s use in orthopedic and soft tissue surgery, encompassing procedures on the foot and ankle, as well as other therapies that steer clear of direct interaction with articular cartilage.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

It’s noteworthy that ZYNRELEF had previously received approval for specific surgical procedures in adults, including foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty. This extended indication for ZYNRELEF is anticipated to cover an estimated 13 million procedures annually, reflecting an 86% increase from the previously indicated procedures.

To secure this expanded labeling, Heron conducted comprehensive studies involving cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty. Importantly, the new clinical trials did not reveal any distinctive safety issues, and the blood concentrations of bupivacaine and meloxicam were consistent with the established experience following ZYNRELEF administration.

The expanded indication holds the potential to bring about a transformative shift in patient care, furnishing healthcare professionals with a versatile and efficient solution for postoperative pain management across an expanded spectrum of surgical procedures. Coupled with the recent collaboration with CrossLink and the anticipated approval of the Vial Access Needle (VAN) later this year, this development is expected to exert a substantial positive impact on ZYNRELEF and the overall company.

This regulatory approval positions Heron to offer an advanced, safe, and effective alternative to an even broader spectrum of healthcare providers and patients seeking sustained non-opioid pain control following challenging surgical procedures. The approval underscores Heron’s steadfast dedication to providing meaningful solutions that address unmet medical needs in acute care and oncology settings.

Most Popular